Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Propionyl carnitine

Drug Profile

Propionyl carnitine

Alternative Names: Dromos; Levocarnitine proprionate; Levocarnitine proprionate hydrochloride; PLC; Propionyl-L-carnitine; Propionyl-L-carnitine HCl; Propionyl-L-carnitine hydrochloride; ST 261

Latest Information Update: 28 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sigma-tau SpA
  • Developer Lee's Pharmaceutical; sigma-tau SpA
  • Class Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Trimethyl ammonium compounds; Vascular disorder therapies; Vitamins
  • Mechanism of Action Free radical scavengers; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial occlusive disorders
  • Discontinued Angina pectoris; Heart failure; Kidney disorders; Myocardial ischaemia; Ulcerative colitis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Peripheral-arterial-occlusive-disorders(In volunteers) in China (PO, Tablet)
  • 24 Jun 2018 Biomarkers information updated
  • 02 Apr 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Austria, France, Germany, Hungary, Latvia, Lithuania, Poland and Spain (NCT01567956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top